The effect of Eplerenone the Renal Insulin Resistance syndrome

Authors
Category Primary study
Registry of TrialsUMIN Clinical Trials Registry
Year 2012
INTERVENTION: control group 1 medication of pracebo for 3 years intervention group 1 medication of Eplerenone(25mg/day) for 3 years CONDITION: Chronic Kidney Disease PRIMARY OUTCOME: HOMA‐IR, rate of change in eGFR, incidence of CVD, mortality rate SECONDARY OUTCOME: ABI, PWV, IMT, markers of tubular damage,; TP/Cr, BNP INCLUSION CRITERIA: 1.CKD patient 2.HOMA‐IR1.6 3.Serum Aldosterone level>150pg/ml
Epistemonikos ID: 17ab0e3d63a47e8187a7e0a387ac9b76b4c09fee
First added on: Aug 22, 2024